MXPA02010410A - Tratamiento de los sindromes de fibromialgia y de fatiga cronica. - Google Patents

Tratamiento de los sindromes de fibromialgia y de fatiga cronica.

Info

Publication number
MXPA02010410A
MXPA02010410A MXPA02010410A MXPA02010410A MXPA02010410A MX PA02010410 A MXPA02010410 A MX PA02010410A MX PA02010410 A MXPA02010410 A MX PA02010410A MX PA02010410 A MXPA02010410 A MX PA02010410A MX PA02010410 A MXPA02010410 A MX PA02010410A
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
quinoline
trans
day
acceptable salt
Prior art date
Application number
MXPA02010410A
Other languages
English (en)
Spanish (es)
Inventor
Robert B Mccall
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of MXPA02010410A publication Critical patent/MXPA02010410A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
MXPA02010410A 2000-04-21 2001-04-17 Tratamiento de los sindromes de fibromialgia y de fatiga cronica. MXPA02010410A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19896000P 2000-04-21 2000-04-21
PCT/US2001/010806 WO2001087308A1 (en) 2000-04-21 2001-04-17 Treatment of fibromyalgia and chronic fatigue syndrome

Publications (1)

Publication Number Publication Date
MXPA02010410A true MXPA02010410A (es) 2003-04-25

Family

ID=22735613

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02010410A MXPA02010410A (es) 2000-04-21 2001-04-17 Tratamiento de los sindromes de fibromialgia y de fatiga cronica.

Country Status (12)

Country Link
EP (1) EP1280530A1 (zh)
JP (1) JP2004502651A (zh)
KR (1) KR20020089510A (zh)
CN (1) CN1418099A (zh)
AU (2) AU5522301A (zh)
BR (1) BR0110188A (zh)
CA (1) CA2404704A1 (zh)
HK (1) HK1054190A1 (zh)
MX (1) MXPA02010410A (zh)
NZ (1) NZ522115A (zh)
WO (1) WO2001087308A1 (zh)
ZA (1) ZA200208272B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
EP4009973A4 (en) * 2019-08-07 2023-08-23 Aclipse One, Inc. PHARMACEUTICAL COMPOSITIONS OF (6AS) -6-METHYL-5,6,6A,7-TETRAHYDRO-4H-DIBENZO[DE,G]QUINOLINE-10,11-DIOL

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073555A (en) * 1988-04-04 1991-12-17 George D. McAdory Medicaments intended for combined use in the improvement of lymphocyte function to lower cholesterol levels
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IT1304904B1 (it) * 1998-09-11 2001-04-05 Eisai Co Ltd Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
DE60022916T2 (de) * 1999-07-01 2006-07-06 Pharmacia & Upjohn Co. Llc, Kalamazoo Reboxetin zur Behandlung von peripheren Neuropathien
DE19938823A1 (de) * 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
NZ531171A (en) * 2000-04-21 2005-03-24 Upjohn Co Cabergoline-type compounds for treating fibromyalgia and chronic fatigue syndrome
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia

Also Published As

Publication number Publication date
WO2001087308A1 (en) 2001-11-22
BR0110188A (pt) 2003-03-05
AU2001255223B2 (en) 2004-10-21
JP2004502651A (ja) 2004-01-29
HK1054190A1 (zh) 2003-11-21
CA2404704A1 (en) 2001-11-22
AU5522301A (en) 2001-11-26
EP1280530A1 (en) 2003-02-05
ZA200208272B (en) 2004-01-26
NZ522115A (en) 2004-07-30
WO2001087308B1 (en) 2002-05-16
CN1418099A (zh) 2003-05-14
KR20020089510A (ko) 2002-11-29

Similar Documents

Publication Publication Date Title
US9700548B2 (en) Antihistamines combined with dietary supplements for improved health
US6281207B1 (en) Treatment of movement disorders by administration of mirtazapine
RU2221563C2 (ru) Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона
US20060039867A1 (en) Method for treating sleep-related breathing disorders with setiptiline
RU2488392C2 (ru) Лечение агонистом мелатонина
JPH05507731A (ja) 物質乱用障害の治療用医薬組成物
EP1634597A1 (en) Compositions comprising dextromethorphan and quinidine or quinine for the treatment of emotional lability
KR19990067527A (ko) 동통의 치료를 위한 에피나스틴의 용도
JP2002523447A (ja) ５−ｈｔ６アンタゴニストの使用
JP2002541097A (ja) 線維筋痛症及び関連症状の治療におけるフルピルチン
EA003142B1 (ru) Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения
US20030212085A1 (en) Treatment of fibromyalgia and chronic fatigue syndrome
US8461146B2 (en) Pharmaceutical composition for the treatment of premature ejaculation
WO2018148737A1 (en) 5-ht2a serotonin receptor serotonin receptor inverse agonists useful for the prophylaxis and treatment of parkinsonian symptoms associated with a neurodegenerative disease
JP2002511087A (ja) ブプレノルフィンを用いる慢性疲労症候群および線維筋痛症の治療方法
ZA200209272B (en) Aromatic polyurethane polyol.
JPS63243028A (ja) 基本的うつ病を軽減するためのうつ病治療剤
AU2001255223B2 (en) Treatment of fibromyalgia and chronic fatigue syndrome
AU2001255223A1 (en) Treatment of fibromyalgia and chronic fatigue syndrome
WO2002083141A1 (en) Treatment of fibromyalgia and chronic fatigue syndrome
US20040214877A1 (en) Treatment of fibromyalgia and related fatigue syndromes using antagonists or partial agonists of 5HT1a receptors
US6841557B2 (en) Compounds for the treatment of addictive disorders
JP2003507352A (ja) 急なベンゾジアゼピン離脱処置のためのシアメマジンの使用
CZ355998A3 (cs) Pyridil a pyrimidylpiperaziny pro léčení poruch způsobených odejmutím drogy
CA1285880C (en) Use of terguride as a geriatric agent